Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm

Fabio Facchetti, Stefano A. Pileri, Claudio Agostinelli, Maria Paola Martelli, Marco Paulli, Adriano Venditti, Massimo F. Martelli, Brunangelo Falini

Research output: Contribution to journalArticlepeer-review


Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML) and blastic plasmacytoid dendritic cell neoplasm have been included as new entities in the 4th edition (2008) WHO classification of myeloid neoplasms. These conditions may show clinical and pathological overlapping features (leukemic and skin involvement, and expression of macrophage markers). In this study, we provide evidence that aberrant cytoplasmic dislocation of nucleophosmin - the immunohistochemical surrogate for NPM1 mutations - allows the two entities to be genetically separated. In fact, nucleophosmin is consistently cytoplasmic in NPMc+ AML (because of the presence of NPM1 mutations), whilst it is nucleus-restricted (predictive of a germline NPM1 gene) in blastic plasmacytoid dendritic cell neoplasm. Our results clearly point to cytoplasmic nucleophosmin (a full predictor of NPM1 mutations) as a new marker for distinguishing NPMc+ AML and blastic plasmacytoid dendritic cell neoplasm, further clarify the cell of origin of NPMc+ AML, and justify the inclusion of these pathological conditions as separate entities in the new WHO classification.

Original languageEnglish
Pages (from-to)285-288
Number of pages4
Issue number2
Publication statusPublished - Feb 2009


  • Acute myeloid leukemia
  • Antibodies
  • Immunohistochemistry
  • Mutations
  • NPM1
  • Nucleophosmin
  • Plasmacytoid dendritic cells

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm'. Together they form a unique fingerprint.

Cite this